Diagnosis and management of smouldering myeloma

Clinical management of plasma cell leukaemia

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer

Neoadjuvant nivolumab for resectable lung cancer

Biomarkers of pembrolizumab response in head and neck cancer

Phase I taselisib results and a cell-free DNA assay

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099

Development and clinical indications of PARP inhibitors

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

First-in-human trial results of RET targeted BLU-667

Treating RET alterations with novel therapy BLU-667

Tandem duplications in triple negative breast cancer